Tentt

Everest to Buy Hasten Bio Singapore Unit for $150M

Announced
HealthcareDivestiture

Deal Overview

Everest Medicines Ltd. agreed to acquire the Singapore-based commercial unit of Hasten Biopharmaceuticals (Asia) Ltd. for $150 million up front. The deal grants Everest market authorization holder rights to 14 marketed products originally developed by Takeda Pharmaceutical Co. Ltd.

The excerpt also references a $250 million deal value, but the stated upfront consideration is $150 million. The transaction is announced and subject to standard closing processes for commercial-unit transfers.

Key Details

Transaction
Everest Medicines acquires Hasten Biopharmaceuticals Asia
Deal Size
Over $100M
Reported Value
$150 million

Filed under

Source

Read full article on bioworld.com

via GN - agreed to acquire million · April 9, 2026

Powered by Tentt

Source healthcare deals for your firm

Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.

Book a 30-min intro call

Related Deals

See all Healthcare deals →